Trials / Completed
CompletedNCT01275196
Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients
ENESTChina: A Phase III Multi-center, Open-label, Randomized Study of Nilotinib Versus Imatinib in Chinese Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 267 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nilotinib | |
| DRUG | Imatinib |
Timeline
- Start date
- 2011-04-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2011-01-12
- Last updated
- 2016-04-08
- Results posted
- 2015-12-09
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01275196. Inclusion in this directory is not an endorsement.